The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook
Dendritic cells (DC) are key phagocytic cells that play crucial roles in both the innate and adaptive immune responses against the human immunodeficiency virus type 1 (HIV-1). By processing and presenting pathogen-derived antigens, dendritic cells initiate a directed response against infected cells....
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2020-01-01
|
| Series: | Journal of Immunology Research |
| Online Access: | http://dx.doi.org/10.1155/2020/9470102 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560708074602496 |
|---|---|
| author | Hager Mohamed Vandana Miller Stephen R. Jennings Brian Wigdahl Fred C. Krebs |
| author_facet | Hager Mohamed Vandana Miller Stephen R. Jennings Brian Wigdahl Fred C. Krebs |
| author_sort | Hager Mohamed |
| collection | DOAJ |
| description | Dendritic cells (DC) are key phagocytic cells that play crucial roles in both the innate and adaptive immune responses against the human immunodeficiency virus type 1 (HIV-1). By processing and presenting pathogen-derived antigens, dendritic cells initiate a directed response against infected cells. They activate the adaptive immune system upon recognition of pathogen-associated molecular patterns (PAMPs) on infected cells. During the course of HIV-1 infection, a successful adaptive (cytotoxic CD8+ T-cell) response is necessary for preventing the progression and spread of infection in a variety of cells. Dendritic cells have thus been recognized as a valuable tool in the development of immunotherapeutic approaches and vaccines effective against HIV-1. The advancements in dendritic cell vaccines in cancers have paved the way for applications of this form of immunotherapy to HIV-1 infection. Clinical trials with patients infected with HIV-1 who are well-suppressed by antiretroviral therapy (ART) were recently performed to assess the efficacy of DC vaccines, with the goal of mounting an HIV-1 antigen-specific T-cell response, ideally to clear infection and eliminate the need for long-term ART. This review summarizes and compares methods and efficacies of a number of DC vaccine trials utilizing autologous dendritic cells loaded with HIV-1 antigens. The potential for advancement and novel strategies of improving efficacy of this type of immunotherapy is also discussed. |
| format | Article |
| id | doaj-art-f518713f3b6042228b308dfb77a989f0 |
| institution | Kabale University |
| issn | 2314-8861 2314-7156 |
| language | English |
| publishDate | 2020-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Journal of Immunology Research |
| spelling | doaj-art-f518713f3b6042228b308dfb77a989f02025-02-03T01:26:58ZengWileyJournal of Immunology Research2314-88612314-71562020-01-01202010.1155/2020/94701029470102The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and OutlookHager Mohamed0Vandana Miller1Stephen R. Jennings2Brian Wigdahl3Fred C. Krebs4Department of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USADepartment of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USADepartment of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USADepartment of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USADepartment of Microbiology and Immunology, Center for Molecular Virology and Translational Neuroscience, Institute for Molecular Medicine and Infectious Disease, Drexel University College of Medicine, Philadelphia, PA 19102, USADendritic cells (DC) are key phagocytic cells that play crucial roles in both the innate and adaptive immune responses against the human immunodeficiency virus type 1 (HIV-1). By processing and presenting pathogen-derived antigens, dendritic cells initiate a directed response against infected cells. They activate the adaptive immune system upon recognition of pathogen-associated molecular patterns (PAMPs) on infected cells. During the course of HIV-1 infection, a successful adaptive (cytotoxic CD8+ T-cell) response is necessary for preventing the progression and spread of infection in a variety of cells. Dendritic cells have thus been recognized as a valuable tool in the development of immunotherapeutic approaches and vaccines effective against HIV-1. The advancements in dendritic cell vaccines in cancers have paved the way for applications of this form of immunotherapy to HIV-1 infection. Clinical trials with patients infected with HIV-1 who are well-suppressed by antiretroviral therapy (ART) were recently performed to assess the efficacy of DC vaccines, with the goal of mounting an HIV-1 antigen-specific T-cell response, ideally to clear infection and eliminate the need for long-term ART. This review summarizes and compares methods and efficacies of a number of DC vaccine trials utilizing autologous dendritic cells loaded with HIV-1 antigens. The potential for advancement and novel strategies of improving efficacy of this type of immunotherapy is also discussed.http://dx.doi.org/10.1155/2020/9470102 |
| spellingShingle | Hager Mohamed Vandana Miller Stephen R. Jennings Brian Wigdahl Fred C. Krebs The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook Journal of Immunology Research |
| title | The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook |
| title_full | The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook |
| title_fullStr | The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook |
| title_full_unstemmed | The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook |
| title_short | The Evolution of Dendritic Cell Immunotherapy against HIV-1 Infection: Improvements and Outlook |
| title_sort | evolution of dendritic cell immunotherapy against hiv 1 infection improvements and outlook |
| url | http://dx.doi.org/10.1155/2020/9470102 |
| work_keys_str_mv | AT hagermohamed theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT vandanamiller theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT stephenrjennings theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT brianwigdahl theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT fredckrebs theevolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT hagermohamed evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT vandanamiller evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT stephenrjennings evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT brianwigdahl evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook AT fredckrebs evolutionofdendriticcellimmunotherapyagainsthiv1infectionimprovementsandoutlook |